Unidade Local De Saude De Entre O Douro E Vouga E.P.E. — Clinical Trial Site

46 Registered trials

15 Currently recruiting

Organisation

Unidade Local De Saude De Entre O Douro E Vouga E.P.E.

Location

Santa Maria Da Feira, Portugal

Identifier

ORG-100044162

Address

Rua Dr Candido De Pinho, 4520-211, Portugal

Departments

#5703: Serviço Neurologia
10005:Gastroenterologia
1809: Serviço Neurologia
2709: Serviço Cardiologia
3109:Cardiologia
Cardiology
Gastroenterology
Gastrology
Medical Oncology Service
N/A
Neurology
Neurology Department
Oftalmologia
Oncology
Otorhinolaryngology service
PT10006, Serviço de Gastrenterologia
PT10007: Serviço de Gastrenterologia
Servico de Cardiologia
Serviço de Gastrenterologia
Serviço de Medicina Interna
Serviço de Neurologia
Servico Oncologia Medica
Unidade Local de Saude de Entre Douro e Vouga - Hospital de Sao Sebastiao

Clinical trials at this site (46)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
An extension study to investigate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chr… Pending

2025-522983-33-00 Chronic rhinosinusitis with nasal polyps 5
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Pending

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5
A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn'… Recruiting

2024-513054-30-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting

2022-502286-16-00 Primary Generalized Tonic-Clonic Seizures 5 2023-10-27
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
A Study to Test the Effectiveness and Safety of RO7790121 for induction and maintenance therapy in Patients with Moderately to Severely Acti… Recruiting

2024-513053-69-00 Moderately to Severely Active Crohn's Disease (CD) 5 2025-04-16
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
A study to determine if BHV-7000 is safe in adults with refractory focal onset epilepsy Recruiting

2023-508813-18-00 Refractory Focal Onset Epilepsy 4 2024-12-18
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy Recruiting

2023-508811-21-00 Refractory Focal Onset Epilepsy 10 2024-09-25
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Primary generalized tonic-clonic seizures 5 2024-02-14
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting

2022-502281-25-00 Focal Onset Seizures 5 2023-09-27
A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous a… Recruiting

2023-509357-31-00 Multiple Sclerosis (MS) 1 2021-06-01
A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (antiIL33 mAb) in participants with inadequately-controlled… Ended

2024-516814-39-00 Chronic rhinosinusitis with nasal polyps 5 2025-05-20
A Study to Assess the Effectiveness and Safety of RO7790121 for Induction Therapy in Participants with Moderately to Severely Active Ulcerat… Ended

2024-513015-27-00 Moderately to Severely Active Ulcerative Colitis (UC) 5 2025-01-09
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy… Ended

2023-503669-50-00 Moderate-to-Severe Thyroid Eye Disease 5 2023-12-27
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04